Kuros Biosciences Report Results for Two Clinical Trials in Patients with Degenerative Disc Disease (DDD)
Shots:
- The (MAXA) trial evaluates MagnetOs vs autograft for posterolateral fusion in patients (n=100) that require up to 4-level instrumented posterolateral fusion (T10-S2). The results depicted a 73% higher fusion rate with MagnetOs vs autograft
- Moreover, the (STRUCTURE) trial evaluates the safety & efficacy of Fibrin-PTH (KUR-113) vs autograft in single-level TLIF procedures in patients with DDD. The randomized part of the study depicted considerable safety profiles in both experimental arms
- Considering the superiority shown by MagnetOs as compared to autograft in difficult-to-treat patients, Kuros has decided to not proceed with the P-III evaluation of Fibrin-PTH and focus on continuing investment in its MagnetOs program
Ref: PRNewswire | Image: Zavation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
